- Home
- ARWR
as 04-18-2025 1:31pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 1.7B | IPO Year: | 1993 |
| Target Price: | $41.44 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.57 - $30.41 | Next Earning Date: | 05-08-2025 |
| Revenue: | $2,500,000 | Revenue Growth: | -98.62% |
| Revenue Growth (this year): | 4380.43% | Revenue Growth (next year): | 64.24% |
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 13 '25 | Sell | $15.07 | 51,425 | $774,974.75 | 4,062,377 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 3 '25 | Sell | $17.53 | 300,000 | $5,274,333.67 | 4,062,377 | |
| OLUKOTUN ADEOYE Y | ARWR | Director | Jan 23 '25 | Sell | $21.00 | 959 | $20,139.00 | 35,781 |
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
ARWR: Raising target price to $14.00
MT Newswires
4 days ago
Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer
Business Wire
4 days ago
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
Argus Research
5 days ago
Daily – Vickers Top Buyers & Sellers for 04/14/2025
MT Newswires
5 days ago
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,533,337, According to a Recent SEC Filing
Argus Research
11 days ago
ARWR: Lowering target price to $10.00
Business Wire
15 days ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Argus Research
18 days ago
ARWR: Lowering target price to $13.00
Compare ARWR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.